Clinical Trials Directory

Trials / Completed

CompletedNCT00564213

Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
36 (estimated)
Sponsor
Instituto de Olhos de Goiania · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

To evaluate and compare the effect of the prophylactic use of two different exposure times of mitomycin C (MMC) 0.02% to inhibit haze formation after photorefractive keratectomy (PRK) for high myopia (\> -7.0 D). Methods: Forty six eyes of twenty three patients, 8 men and 15 women, with high myopia were included in this prospective study. Mean age at the time of PRK plus MMC was 31.7 years. Before PRK, the mean spherical equivalent was -8.50 D (range, -7.25 to -10.50 D). In each patient, one eye was randomly assigned to PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds (Group 1) and the fellow eye, for 30 seconds (Group 2).The inclusion criteria were high myopia, no central corneal opacity and inadequate corneal thickness to allow a safe Laser in situ keratomileusis procedure. Refraction, uncorrected visual acuity, best spectacle-corrected visual acuity (BSCVA), and slit-lamp evidence of corneal opacity (haze) were evaluated over 12 months

Conditions

Interventions

TypeNameDescription
DRUGPRK and a single intraoperative topical application of mitomycin C 0.02% for 15 secondsMitomycin 0.02%

Timeline

Start date
2005-03-01
Completion
2007-09-01
First posted
2007-11-27
Last updated
2008-11-26

Source: ClinicalTrials.gov record NCT00564213. Inclusion in this directory is not an endorsement.